首页> 外国专利> Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof

Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof

机译:改进的方法,其用于提高哺乳动物细胞培养物中的抗体生产率并最小化其下游的配制过程以及由此获得的稳定的抗体制剂

摘要

The invention, describes an efficient platform for antibody manufacturing and formulation, that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include lgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and lgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.
机译:本发明描述了用于抗体生产和配制的有效平台,该平台提供:i)具有改进的进料策略的细胞培养过程,导致2 gm / L至5 gm / L的高抗体滴度; ii)改进的纯化工艺,显示出最佳的回收率,高纯度单体含量,最小的聚集/颗粒形成,最小的杂质含量; iii)高浓度稳定的液体制剂,在不同温度范围内具有最佳的渗透压和低粘度,并且没有聚集。优选的抗体包括对E蛋白的结构域III中的登革热病毒表位具有特异性的IgG1单克隆抗体和对狂犬病毒表面G糖蛋白具有特异性的IgG1单克隆抗体。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号